Zymeworks (ZYME)
(Delayed Data from NSDQ)
$16.25 USD
-0.24 (-1.46%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $16.24 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 16.25 -0.24(-1.46%)
Will ZYME be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus
Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates
Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
Other News for ZYME
ZYME forms 180 Bullish Setup on September 18
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Zymeworks (ZYME)
Shooting Star Candlestick appears for ZYME after 0.19% move
Upper Bollinger Band Walk appears for ZYME after 0.56% move
ZYME forms Slingshot Bullish on September 15